Cargando…

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response

BACKGROUND: CD47 is an integral membrane protein that alters adaptive immunosurveillance when bound to the matricellular glycoprotein thrombospondin-1 (TSP1). We examined the impact of the CD47/TSP1 signaling axis on melanoma patient response to anti-PD-1 therapy due to alterations in T cell activat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stirling, Elizabeth R, Terabe, Masaki, Wilson, Adam S, Kooshki, Mitra, Yamaleyeva, Liliya M, Alexander-Miller, Martha A, Zhang, Wei, Miller, Lance D, Triozzi, Pierre L, Soto-Pantoja, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685258/ https://www.ncbi.nlm.nih.gov/pubmed/36418073 http://dx.doi.org/10.1136/jitc-2022-004712

Ejemplares similares

Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity
por: Xi, Qing, et al.
Publicado: (2020)

IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020)

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
por: Efimova, Iuliia, et al.
Publicado: (2020)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021)

Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity
por: Wang, Zining, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity
por: Kalim, Khalid W, et al.
Publicado: (2022)

BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity
por: Wu, Bogang, et al.
Publicado: (2023)

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
por: Won, Ji Eun, et al.
Publicado: (2022)

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021)

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
por: Zhang, Cangang, et al.
Publicado: (2021)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells
por: Bai, Xiaowu, et al.
Publicado: (2022)

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
por: Hu, Jinyang, et al.
Publicado: (2022)

Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens
por: Jang, Hyun J, et al.
Publicado: (2023)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

Amino acids and RagD potentiate mTORC1 activation in CD8(+) T cells to confer antitumor immunity
por: Zhang, Yiwen, et al.
Publicado: (2021)

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
por: Yan, Wan-Lun, et al.
Publicado: (2021)

Oral SMEDDS promotes lymphatic transport and mesenteric lymph nodes target of chlorogenic acid for effective T-cell antitumor immunity
por: Ye, Jun, et al.
Publicado: (2021)

Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation
por: Deng, Guoliang, et al.
Publicado: (2022)

TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway
por: Lu, Tianqi, et al.
Publicado: (2023)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
por: Zammarchi, Francesca, et al.
Publicado: (2020)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancer
por: Sima, Livia Elena, et al.
Publicado: (2021)

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
por: Jacoberger-Foissac, Celia, et al.
Publicado: (2020)

Estrogen receptor beta signaling in CD8(+) T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch
por: Yuan, Bin, et al.
Publicado: (2021)

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts
por: Woolaver, Rachel A, et al.
Publicado: (2021)

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
por: Cueto, Francisco J, et al.
Publicado: (2021)

Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
por: Noyes, David, et al.
Publicado: (2022)

ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
por: Jin, Won Jong, et al.
Publicado: (2023)

CD47 Activation by Thrombospondin-1 in Lymphatic Endothelial Cells Suppresses Lymphangiogenesis and Promotes Atherosclerosis
por: Singla, Bhupesh, et al.
Publicado: (2023)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_njhtura0ddm44lj9n32rm027su